With $26M Series D, Antibody Platform Developer Sutro Biopharma To Prep Its Own Products
This article was originally published in The Pink Sheet Daily
The decade-old San Francisco antibody developer previously has relied on platform partnerships, but now will attempt to bring a candidate – likely a bi-specific antibody – into the clinic within 18 months. Six investors, including three corporate VCs, composed the returning syndicate.
You may also be interested in...
Celgene Corp. has deepened its investment in antibody R&D, striking a collaboration with Sutro Biopharma to design and develop next-gen antibodies and to manufacture a proprietary Celgene candidate. Sutro gets cash, biobucks, and hi-profile validation of its multi-faceted non-cell antibody platform.
The onetime Celera CEO says his new attempt to centralize biological information into a massive database could lead to breakthroughs that extend the human life span. Behind that bold goal is a more mundane data-licensing strategy that, although not splashy, could still improve medicine.
Do high biotech share prices portend stock-heavy deal-making in lieu of all-cash transactions? Also, Biogen shares the risk with Eisai in an Alzheimer’s deal, while newly public Genocea and cell therapy specialist NeoStem both teamed with Harvard researchers.